ReviewFrontiers in pharmacology2025
Biotechnological production of terpenoids using cell factories.
Review in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Metabolic engineering strategies: utilizing different microbial strains and advanced technologies for the synthesis of high-valued terpenoids.Antonie van Leeuwenhoek · 2026Review
- The Mevalonate Pathway: Innovations, Applications, and Challenges in Biotechnology with Emphasis on Fungal Biology.Journal of fungi (Basel, Switzerland) · 2026Review
Corrections and comments
- Erratum issued
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Terpenoids, as one of the most abundant natural products in nature, have important application values in the fields of medicine, food, and daily chemicals industries. Beyond their industrial applications, terpenoids offer notable nutritional benefits to humans and are extensively utilized for their pharmacological properties. Conventional production approaches, such as plant extraction and chemical synthesis, are increasingly constrained by limited resources and environmental concerns. Consequently, biotechnology has emerged as a pivotal strategy for terpenoid synthesis, owing to its advantages in efficiency, sustainability, and precise regulatory capabilities. This review provides a comprehensive overview of recent progress in biotechnological production of terpenoids, with a particular emphasis on metabolic and enzyme engineering and enzyme engineering. Furthermore, we explored the potential of using computational and artificial intelligence technologies for the rational design and construction of high-performance cell factories is discussed, providing promising pathways for the biosynthesis of terpenoids in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.